Fig. 6
From: Mast cell marker gene signature in head and neck squamous cell carcinoma
Estimation of the roles of the mast cell gene signature (MCS) in predicting immune checkpoint gene expression and immunotherapeutic response. Expression of immune checkpoint genes in different risk groups of the training cohort, violin plot of CD274 (PD-L1) (A), LAG3 (B), CTLA4 (C), TIGIT (D), and IDO1 (E) expression in the low- and high-risk groups. ***P < 0.001. Correlation between the risk scores and immune checkpoint gene expression, scatter plot of CD274 (PD-L1) (F), LAG3 (G), CTLA4 (H), TIGIT (I), and IDO1 (J) expression with risk scores. Association between the immunophenoscore and MCS in patients with head and neck squamous cell carcinoma (HNSCC) based on The Cancer Immunome Database CTLA-4−PD-1− (K), CTLA-4−PD-1+ (L), CTLA-4+PD-1− (M), CTLA-4+PD-1+ (L)